BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 19076962)

  • 1. In vivo magnetic resonance spectroscopy of gynaecological tumours at 3.0 Tesla.
    Booth SJ; Pickles MD; Turnbull LW
    BJOG; 2009 Jan; 116(2):300-3. PubMed ID: 19076962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
    Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK
    J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The accurate staging of ovarian cancer using 3T magnetic resonance imaging--a realistic option.
    Booth SJ; Turnbull LW; Poole DR; Richmond I
    BJOG; 2008 Jun; 115(7):894-901. PubMed ID: 18485169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration.
    Mahon MM; Williams AD; Soutter WP; Cox IJ; McIndoe GA; Coutts GA; Dina R; deSouza NM
    NMR Biomed; 2004 Feb; 17(1):1-9. PubMed ID: 15011245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors.
    Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX
    Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined DCE-MRI and single-voxel 2D MRS for differentiation between benign and malignant breast lesions.
    Lipnick S; Liu X; Sayre J; Bassett LW; Debruhl N; Thomas MA
    NMR Biomed; 2010 Oct; 23(8):922-30. PubMed ID: 20878970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.
    Canese R; Pisanu ME; Mezzanzanica D; Ricci A; Paris L; Bagnoli M; Valeri B; Spada M; Venditti M; Cesolini A; Rodomonte A; Giannini M; Canevari S; Podo F; Iorio E
    NMR Biomed; 2012 Apr; 25(4):632-42. PubMed ID: 22020805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry in gynaecological pathology: a review.
    Marjoniemi VM
    Pathology; 2004 Apr; 36(2):109-19. PubMed ID: 15203746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo proton MR spectroscopy (1H-MRS) for evaluation of human gastric carcinoma.
    Mun CW; Cho JY; Shin WJ; Choi KS; Eun CK; Cha SS; Lee J; Yang YI; Nam SH; Kim J; Lee SY
    Magn Reson Imaging; 2004 Jul; 22(6):861-70. PubMed ID: 15234456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton MR spectroscopy of the prostate.
    Mueller-Lisse UG; Scherr MK
    Eur J Radiol; 2007 Sep; 63(3):351-60. PubMed ID: 17709223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla.
    Stanwell P; Russell P; Carter J; Pather S; Heintze S; Mountford C
    Invest Radiol; 2008 Oct; 43(10):745-51. PubMed ID: 18791417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification.
    Lee CW; Lee JH; Kim DH; Min HS; Park BK; Cho HS; Kang HG; Suh JS; Ehara S
    Clin Imaging; 2010; 34(1):47-52. PubMed ID: 20122519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo proton magnetic resonance spectroscopy of breast lesions: an update.
    Tse GM; Yeung DK; King AD; Cheung HS; Yang WT
    Breast Cancer Res Treat; 2007 Sep; 104(3):249-55. PubMed ID: 17051424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance spectroscopy of premalignant and malignant endometrial disorders: a feasibility of in vivo study.
    Celik O; Hascalik S; Sarac K; Meydanli MM; Alkan A; Mizrak B
    Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):241-5. PubMed ID: 15653212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [1H magnetic resonance spectroscopy of the prostate].
    Mueller-Lisse UG; Scherr M
    Radiologe; 2003 Jun; 43(6):481-8. PubMed ID: 12827263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of single voxel 1H MR spectroscopy of bone tumors: differentiation of benign from malignant tumors.
    Zhang J; Cheng K; Ding Y; Liang W; Ding Y; Vanel D; Cheng X
    Eur J Radiol; 2013 Dec; 82(12):2124-8. PubMed ID: 22169357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of metabolite changes in the transition from pre-invasive to invasive cervical cancer measured using (1)H and (31)P magic angle spinning MRS of intact tissue.
    De Silva SS; Payne GS; Thomas V; Carter PG; Ind TE; deSouza NM
    NMR Biomed; 2009 Feb; 22(2):191-8. PubMed ID: 18833545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo detection of choline in ovarian tumors using 3D magnetic resonance spectroscopy.
    Esseridou A; Di Leo G; Sconfienza LM; Caldiera V; Raspagliesi F; Grijuela B; Hanozet F; Podo F; Sardanelli F
    Invest Radiol; 2011 Jun; 46(6):377-82. PubMed ID: 21467947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preinvasive and invasive cervical cancer: an ex vivo proton magic angle spinning magnetic resonance spectroscopy study.
    Mahon MM; deSouza NM; Dina R; Soutter WP; McIndoe GA; Williams AD; Cox IJ
    NMR Biomed; 2004 May; 17(3):144-53. PubMed ID: 15137039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of choline measurement by proton MR spectroscopy in patients with malignant tumors.
    Lee J; Yamaguchi T; Abe A; Shizukuishi K; Uemura H; Miyagi E; Sakata K; Inoue T
    Radiat Med; 2004; 22(3):148-54. PubMed ID: 15287529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.